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Introduction
Chronic Recurrent Multifocal Osteomyelitis (CRMO) is
classified among the rare auto-inflammatory diseases. It
has a genetic predisposition and a pathogenesis largely
under investigation. Greek publications regarding
CRMO in pediatric patients are currently absent.
Objectives
The aim of the study was to describe the disease pheno-
type, course and outcome of CRMO Northern Greek
pediatric patients, and assess the disease activity at diag-
nosis by the recently proposed Jansson clinical score,
which has a cut-off value of 39.
Patients and methods
Pediatric patients with a diagnosis of CRMO diagnosed
and followed-up a tertiary University Hospital during
the last decade (2005-2014) were included in this retro-
spective study.
Results
Nine patients (female:8, mean age: 10 yrs) were diag-
nosed with CRMO. The main presenting symptoms in
all patients were inflammatory pain in multiple sites,
mainly in the metaphyses and epiphyses of long bones
in lower limbs (mostly in proximal femur (4/9)) and
swelling (7/9). 6/9 patients reported hip pain and only 1,
clavicular pain. At diagnosis, fever was noted in 5/9
patients, a raised ESR (mean: 52.5mm/h) in 6/9 and
CRP >1mg/dl (≤ 0.5mg/dl) in 5/9. Location of MRI lesions
were vertebral (3/9), thoracic rib (1/9), femur (5/9), fibula
(5/9) and tibia (3/9). The predominantly affected joints
were the hip (5/9) and the ankle (5/9). The calculated
clinical score at diagnosis was >39 in 8/9 patients and 36
in 1 pt.
In respect to treatment, the applied NSAIDs provided
partial pain relief without preventing the disease course
in 8/9 patients; notably, indomethacin had no effect in
1/9 pt. Steroids combined with methotrexate were admi-
nistered in 5/9 patients, but 4/5 required an anti-TNF to
achieve remission. In 2/9 patients antibiotics did not
alter the progress of the disease.
Conclusions
This is the first Greek study that ranks the severity of this
rare multi-faceted disease by Jansson clinical score
recording a rather severe phenotype, despite the insidious
presenting symptoms at onset. As the disease burden was
high, half of the patients required biologics for disease
taming. Jansson score proved an easy tool that can pri-
mary rank the disease severity and identify refractory
cases in need for early aggressive treatment.
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